Document Type

Journal Article

Department/Unit

School of Chinese Medicine

Language

English

Abstract

Drug delivery nanocarriers, especially targeted drug delivery by liposomes are emerging as a class of therapeutics for cancer. Early research results suggest that liposomal therapeutics enhanced efficacy, while simultaneously reducing side effects, owing to properties such as more targeted localization in tumors and active cellular uptake. Here, we highlight the features of immunoliposomes that distinguish them from previous anticancer therapies, and describe how these features provide the potential for therapeutic effects that are not achievable with other modalities. While a large number of studies has been published, the emphasis here is placed on the carbonic anhydrase IX (CA-IX) and the conjugated liposomes that are likely to open a new chapter on drug delivery system by using immunoliposomes to deliver anticancer ingredients to cancer cells in vivo.

Keywords

Anticancer ingredients, Cancer cell penetrating peptides, Carbonic anhydronase IX (CA-IX), Immunoliposomes, In vivo delivery

Publication Date

12-2014

Source Publication Title

International Journal of Molecular Sciences

Volume

16

Issue

1

Start Page

230

End Page

255

Publisher

MDPI

Peer Reviewed

1

Copyright

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Funder

Hong Kong Baptist University Research Grant support and the University Grants Committee of Hong Kong General Research Fund (GRF)

DOI

10.3390/ijms16010230

Link to Publisher's Edition

http://dx.doi.org/10.3390/ijms16010230

ISSN (print)

16616596

ISSN (electronic)

14220067

Share

COinS